XORTX Therapeutics (XRTX) announced the initiation of Investigational New Drug, IND, preparation for its lead program, XRx-026, focused on the treatment of gout. In support of this milestone, XORTX has engaged Allucent, a global contract research organization specializing in regulatory and clinical development. Preparation of the IND will include a comprehensive review of non-clinical, pharmacologic, toxicological, and regulatory progress, and will incorporate the clinical development plan and protocol for a pharmacologic characterization study of XORLO, the Company’s proprietary formulation of oxypurinol, in fed and fasted states. XORTX anticipates submission of the IND in the second half of 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRTX:
- XORTX Therapeutics Reports Financial Results for Mid-2025
- XORTX Therapeutics Completes $114,500 Private Placement to Fund Gout Programs
- Xortx Therapeutics announces planned goals for 2026
- XORTX Therapeutics Advances Gout Program with Strategic 2025/2026 Goals
- XORTX Therapeutics Announces $114,500 Private Placement to Support Gout Programs